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Summary 
Introduction: The prevalence of pediatric obesity has increased worldwide during the last 
decades, and is currently a serious health challenge, as it causes extensive health problems in 
terms of cardiovascular comorbidities and premature mortality. Early detection and treatment 
of childhood obesity is therefore of major importance. 
The Body Mass Index (BMI) is most commonly used to assess adiposity. Although the BMI 
also is considered to be a good predictor for various adverse effects of adiposity, indicators of 
central obesity may have a closer link with cardiometabolic risk as the BMI does not describe 
fat distribution, and visceral fat causes metabolic alterations through multiple pathways. 
Objective: This thesis aims to determine the prevalence of the metabolic syndrome (MetS) as 
defined by Cook et al., and to explore the associations between anthropometric measurements 
(AM) and cardiometabolic risk factors in a group of severely obese children and adolescents 
at Haukeland University Hospital. 
Materials and methods: Ninety-six obese patients with BMI >IOTF 35kg/m
2
 or BMI>30 
kg/m
2
 with comorbidities, aged 5-18 years were recruited from the Obesity outpatient clinic at 
Haukeland University Hospital in Bergen. Information was retrieved from the medical records 
of the participants. Prevalence of the MetS and associations between SD-scores for BMI, 
waist circumference (WC), waist-to-height-ratio (WHtR), and waist-to-sitting height-ratio 
(WSHR), and systolic/diastolic blood pressure (SBP/DBP), HDL, LDL, total cholesterol, 
HbA1c, ALAT, gGT and the MetS were assessed. For correlations and linear regression, 
blood pressure measurements were categorized according to percentiles adjusted for age, 
gender and height. AIC was used to compare the different regression models. All models were 
run with and without adjustment for age and gender. 
Results: The prevalence of the MetS in this group of obese children and adolescents was 
36.9%. Significant moderate to weak correlations were found between all AM and SBP/DBP; 
and between BMI and WSHR, and markers of insulin resistance. Logistic regression models 
adjusted for age and gender showed that BMI, WHtR and WSHR were also significantly 
associated with a SBP >90
th
 percentile, and WC with DBP. BMI was the only measurement 
significantly related to the MetS, and had the lowest AIC when investigating both SBP and 
the MetS. For DBP, WC had the lowest AIC. No significant relations were found with the 
other biomarkers using linear regression adjusted for age and gender. 
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Conclusions: A relatively high prevalence of the MetS underlines the importance of 
screening for cardiometabolic risk factors and providing good treatment for this group of 
severely obese patients.  
Due to weak associations, AM are probably not the main factor affecting the presence of 
cardiometabolic risk in this group of severely obese children and adolescents except for SBP, 
which showed significant associations with all AM. Among the investigated AM, BMI was 
the best to predict cardiometabolic risk.  
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1 Introduction 
1.1 Obesity 
1.1.1 Definition and prevalence 
Overweight and obesity is normally defined using the Body Mass Index (BMI). For children, 
the cut-offs for overweight and obesity are age and gender adjusted as the BMI changes 
during childhood and differs between boys and girls (1, 2). The International Obesity Task 
Force (IOTF) has developed age- and gender-specific BMI-cutoff points which classify 
children and adolescents as normal-weight, overweight, and obese. These cutoff points are 
tied to adult overweight (≥25 kg/m2) and obesity (≥30 kg/m2) thresholds (1). 
The prevalence of pediatric overweight and obesity has increased worldwide during the last 
decades (3), and excessive bodyweight is currently a serious health problem in the European 
Region of the World Health Organization (4). 
A Norwegian study conducted in 2010 found children aged 2-19 years to have a prevalence of 
overweight including obesity of 13.8% and of obesity alone of 2.3%, using the IOTF cutoff 
points (5).  These figures are similar to other Western and Northern countries (5). 
1.1.2 Etiology 
Obesity has a multifactorial etiology. Genetics play an important role in the development of 
obesity (6), and genetic components have been found to contribute between 40% and 70% to 
interindividual variation in obesity (7). Nevertheless, environmental issues such as an 
increased consumption of energy-dense foods and refined carbohydrates combined with a 
sedentary lifestyle and an over-all decline in energy-expenditure are thought to be of greater 
importance, as described in the World Health Organization Technical Report on chronic 
illnesses (8). Further, several non-modifiable risk factors have been identified, including 
parental obesity, gestational weight gain, birth weight, duration of breastfeeding (9), 
socioeconomic status (10), prematurity, rapid catch-up growth (11, 12), and early adipose 
rebound (13). In addition, psychological issues, such as binge- or loss of control eating, can 
contribute to a further development of obesity in children at risk (14). Also, novel research 
has proposed altered microbiota as a result of antibiotic exposure in infancy to result in 
increased BMI in toddlers, and that this may play a role in the development of the obesity 
epidemic (15). 
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1.1.3 Consequences 
In addition to being a serious psychological challenge for children and adolescents (16), 
overweight and obesity cause major health problems in terms of cardiovascular comorbidities 
and premature mortality (17, 18). In this thesis I will focus on the physical consequences of 
obesity, especially the cardiometabolic factors. 
1.1.4 Treatment 
There is limited literature regarding treatment of childhood obesity done in randomized 
controlled trials. Systematical reviews have found that conservative treatment such as 
combined behavioral lifestyle interventions can result in significant weight reduction 
compared with standard care or self-help (19), also, educational interventions including 
behavioral modification can decrease overweight and obesity as well as blood pressure (20). 
The use of drug therapy in children and adolescents is currently not recommended in the 
treatment of overweight and obesity. However, with emergence of new pharmaceutical 
alternatives, drugs might play a role in the future treatment of overweight and obesity as an 
adjunct to conservative treatment (21). 
Surgical interventions have been applied to adolescents in Norway as a part of the ongoing 
intervention study “4XL” at the Center for morbid Obesity in HelseSør-Øst (clinicaltrials.gov 
NCT00923819). Short term results from other countries demonstrate positive effects 
regarding weight-development and social issues, and a lower complication rate than in adults 
(22). However, surgical treatment is currently not considered as a treatment option in 
pediatrics unless life-style treatment has proven inefficient in a metabolic disarranged child or 
adolescent. 
Preventive strategies of overweight and obesity in children and adolescents targeting the 
family, school, and community can have a small effect on weight outcome, but with 
questionable clinical relevance according to a systematic review and meta-analysis (23). 
Further, universal prevention strategies with interventions focusing on the environmental 
arena with policy interventions improving dietary intake and physical activity are thought to 
enhance obesity control rather than an individual strategy with clinical intervention (24). 
The Obesity outpatient clinic at Haukeland University Hospital offers conservative treatment 
of obesity. The treatment is interdisciplinary, with teams of pediatricians, a dietitian, a 
physiotherapist, a psychologist and a specialized nurse. Two treatment methods are used. The 
first is an educational intervention including follow-ups every 3 months with the specialized 
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nurse and every 6 months with a pediatrician. The course of treatment is for two years with 
the possibility of another year if necessary. The other method is based on cognitive behavioral 
treatment with visits to the clinic every week. This method is family based, and it demands 
more from the patient and their families, but also offers a closer follow-up from the attending 
staff and its efficacy is promising. 
Inclusion criteria for treatment at the Obesity outpatient clinic at Haukeland University 
Hospital are having an IOTF BMI above 35 kg/m
2
 or above 30 kg/m
2
 with obesity related 
comorbidity, such as reduced glucose tolerance, hyperinsulinism, hypertension, dyslipidemia, 
sleep apnea, very quick weight gain, or severe concern for weight development (25). When 
included, the patients undergo a physical examination described in detail in the methods 
section.  
 
1.2 Anthropometrics 
Anthropometry is the most commonly used technique in a clinic setting to determine 
overweight and obesity. Anthropometric measures are also used as markers for the outcome 
of treatment. In order to be able to compare anthropometric measurements across age, it is 
common to use percentiles or to calculate standard deviation scores (SDS). 
1.2.1 Body Mass Index 
BMI is routinely assessed as a surrogate measure of adiposity, and thereby defining 
overweight and obesity. It has been validated as a measure of body composition in adults (26-
29), and children (30-32), and has the advantage of being feasible because it is simple, safe 
and inexpensive to obtain (27). 
BMI has earlier been considered to be a good predictor for insulin sensitivity, as Travers et al. 
found that an increasing BMI correlates with increasing insulin levels in children aged 10-15 
years (33). Also, Moussa et al. found a significant correlation between BMI and systolic and 
diastolic blood pressure (SBP and DBP) in children 6-18 years of age (34). However, later 
research accentuates the fact that BMI does not differentiate fat- and fat free tissues (35-37), 
and it is claimed not to describe body fat distribution. As an upper body or centralized 
deposition of body fat is associated with an increased risk for obesity-related metabolic 
complications such as adverse lipoprotein and fasting insulin concentrations (38, 39), the fat-
distribution is of great relevance for assessing this risk. 
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Although an increased BMI is associated with various adverse biochemical and physiologic 
effects of excessive adiposity (30), it would be interesting to investigate whether other 
anthropometric measurements or indexes for children and adolescents have a higher 
correlation as there are some objections to the use of BMI as a marker for the risk of 
developing adiposity-related morbidity. 
1.2.2 Waist circumference 
Waist circumference (WC) has the advantage over BMI that it describes a centralized 
distribution of fat. A peripheral distribution of excessive fat is likely to have an isolating 
effect, whereas a centralized distribution is more likely to consist of ectopic fat, that is fat 
which infiltrates the organs and is metabolically active. There has, however, been some 
debate as to whether the WC is able to distinguish subcutaneous from ectopic fat or not, as 
they are both located in the visceral region. It has been proposed by several authors that this 
measure reflects the intra-abdominal fat which is metabolically active in addition to 
correspond with total body fatness and general abdominal fat in children (40, 41). WC is also 
considered a predictor for the metabolic syndrome (MetS) (42). 
Other anthropometric measures including the WC has also been proposed as better markers 
for metabolic changes as they take into account the distribution of fat. For instance the ratio 
between WC and height, waist-to-height-ratio (WHtR), has been demonstrated to be superior 
to BMI in predicting cardiovascular disease (39, 43, 44). 
1.2.3 Sitting height 
For many years there has been a focus on the WC, however, a research topic which has not 
been explored in particular is whether the height may be of importance when assessing 
metabolic risk. Both BMI and WHtR involve height, but they compose the entire height, 
without consideration of different body parts. Sitting height on the other hand focuses to a 
greater extent on the truncus. Sitting height has been reported to be significantly higher in 
dyslipidemic Chinese children (45), and to correlate with overweight and obesity in Brazilian 
children (46), but beyond this, little is known of its impact on cardiometabolic risk. 
When taking into account that metabolic changes are associated with a fat-accumulation in the 
visceral region of the body, it would be plausible to suggest that anthropometric measures 
including the WC and sitting height may be a stronger predictor for these changes.  
Therefore, there is a need to establish whether other anthropometric measurements than BMI 
better predict obesity-related health risk among children and adolescents. If so, it would have 
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important implications as to whether other measures than height and weight should be 
assessed in the clinical setting.  
 
1.3 Cardiovascular risk factors and the metabolic syndrome 
1.3.1 Cardiometabolic risk factors 
Cardiometabolic risk factors entail alterations increasing the risk for cardiovascular disease 
and metabolic disturbances. Overweight and obesity are associated with an altered metabolic 
state, which increases the risk of cardiovascular disease and a reduced life expectancy (47, 
48). 
1.3.2 The metabolic syndrome 
The MetS is a clustering of selected cardiometabolic risk factors. To date no single 
international standardized criteria have been established to identify the MetS in children. 
However, all existing definitions tend to share these parameters: (1) an obesity estimate, such 
as BMI or WC, (2) elevated blood pressure, (3) altered blood lipids, such as decreased HDL, 
elevated LDL or triglycerides, and (4) a diabetes-related risk factor , such as HOMA-IR, 
elevated fasting glucose or insulin levels, with different cut-off values (49). 
 
In this thesis a definition of the MetS based on the definition proposed by Cook et al. (50) has 
been used. The definition is a modification of the adult criteria, specified by the National 
Cholesterol Educational Program, Adult Treatment Panel III (NCEP ATP III) (51), with the 
closest representative values obtainable from pediatric data.  A review found that in the 
pediatric setting, this is the definition most commonly used (52). Also, for other definitions, 
such as the one proposed by the International Diabetes Federation (IDF) (53), the adaption 
does not apply for children younger than 10 years, which makes it unsuitable for the present 
study sample. 
1.3.3 Pathophysiology of the metabolic syndrome 
Although the pathophysiology of the MetS is not completely understood, there are some main 
factors thought to impact on the development. 
Insulin resistance with hyperinsulinemia seems to be a central factor in the pathogenesis of 
the MetS. An insulin-resistant state interferes with the hormonal actions taking place in the 
liver. Insulin produced in the β-cells of the pancreas travels quickly to the liver via the portal 
vein, and in the presence of the MetS, insulin has a selective dysfunction so that it does not 
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diminish the hepatic glucose output, but rather increases it, and still, like in the normal state, 
increases the de novo lipogenesis, thereby releasing triglycerides to the circulation, causing 
dyslipidemia (54). Further, insulin resistance causes increased renal sodium reabsorption and 
stimulate the sympathetic nervous system which can result in hypertension (55). 
Another factor contributing to the development of the MetS is excessive nutrient intake. 
Nutrient processing in the mitochondria cause ROS formation which can alter the 
mitochondrial function and endoplasmic reticulum which again will lead to defective insulin 
secretion and Diabetes Mellitus type 2 (DMT2) (56). Also, increased excretion of uric acid as 
a result of excessive intake of fructose is thought to cause metabolic alterations, which are 
even more evident in a hyperinsulemic or hypertriglyceridemic state (57). Moreover, 
excessive nutrient intake can result in obesity, defined as the presence of excessive adipose 
tissue, which also contribute to the development. 
Visceral fat is particularly unfortunate as it secrets the inflammatory cytokines TNF-α and IL-
6 and little anti-inflammatory adiponectin as a result of activation and infiltration of 
macrophages in the adipose tissue, while subcutaneous fat first serves as an isolation agent. 
The production of cytokines with pro-inflammatory effects in adipose tissue contributes to an 
increase in lipolysis and hypertriglyceridemia (58, 59), and the lipolysis is further increased 
when insulin resistance is present, and more free fatty acids are released into the circulation 
(60). This becomes part of a vicious circle as an elevated concentration of free fatty acids 
again is thought to cause insulin resistance (60, 61). Altogether, this underpins the allegation 
that increased visceral fat is associated with metabolic alterations. 
There is, however, some debate as to whether insulin resistance and obesity is the cause or a 
consequence of the metabolic alterations as they interfere in a fashion making cause and 
effect hard to differentiate. 
A longitudinal study conducted by Weiss et al. (62) concluded that among severely obese 
children, the absence of the MetS is likely to remain unless further weight gain is achieved, 
which suggest a genetic component in the development of the MetS. This underpin that some 
are susceptible to the MetS to a greater extent than others. A genetic susceptibility for both 
central obesity and for the development of the MetS is probably an underlying cause of the 
development (63). This susceptibility is further reasoned when considering ethnicity, as youth 
of ethnic minorities have been shown to be more obese and more insulin resistant compared 
with their Caucasian counterparts (64). 
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Moreover, for the development of the MetS in adolescence the impact of a temporary insulin 
resistance which occurs during puberty, may be relevant. This state is possibly a result of 
increasing levels of growth hormone and insulin-like growth factor 1 (65). The change can 
worsen the insulin-resistant state in obese youth and accelerate the development of DMT2, or 
the MetS (66). 
1.3.4 Consequences of the metabolic syndrome 
The presence of the MetS entails an increased risk for mortality from cardiovascular diseases 
and all causes in adults (47, 48), and an increase in DMT2 and cardiovascular disease in 
juvenile age (67). Children with obesity are also at increased risk of adolescent and adult 
obesity (17, 68, 69), which again increases the risk of cardiovascular disease in later life. 
The metabolic syndrome is further associated with polycystic ovary syndrome, obstructive 
sleep apnea, hypogonadism and some forms of cancer (70, 71). 
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Figure 1 Mechanisms of obesity-related morbidities. 
Abbreviations: CVD, cardiovascular disease; DMT2, diabetes mellitus type 2; ROS, reactive 
oxygen species 
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1.3.5 NAFLD 
Another change occurring, also associated with overweight, obesity and insulin resistance is 
the infiltration of fat to the liver. Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as 
the presence of steatosis in more than five percent of hepatocytes in the absence of significant 
alcohol consumption, drug use or hereditary diseases (72). Liver transaminases, especially 
ALAT, are commonly considered a surrogate marker for NAFLD and because of its close 
relation to cardiovascular risk factors (73), NAFLD has been suggested to be ‘the hepatic 
manifestation of the MetS’ (66).  
 
1.4 Aims of the investigation 
a) To determine the prevalence of the MetS among obese children and adolescents at the 
Obesity outpatient clinic at Haukeland University Hospital. 
We hypothesize that the prevalence is similar to other European countries 
 
b) To determine whether the SDS for the anthropometrical measurements WC, WHtR, and 
waist-to-sitting height-ratio (WSHR), in addition to BMI, predict cardiometabolic risk factors 
(insulin resistance, altered low density lipoprotein cholesterol (LDL), total cholesterol, 
triglycerides, high density lipoprotein cholesterol (HDL) and liver test (ASAT, ALAT, 
gamma-gt) or the MetS as defined by Cook et al. (50)) better than BMI SDS in obese children 
and adolescents at the Obesity outpatient clinic at Haukeland University Hospital. 
We hypothesize that anthropometric measures can be a valuable predictor. 
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2 Materials and methods 
2.1 Study design and population 
This study has an observational cross-sectional design and has been approved by the Data 
Protection Official (Appendix I). As it can be considered a quality assurance of the treatment 
at the outpatient clinic of obesity, there was no need for approval from the Regional 
Committee of Ethics. 
The cohort consists of 96 patients, of which 46 (47.9%) are boys, with an age range of 5-18 
years. The patients have an IOTF BMI >35 kg/m
2
 or >30 kg/m
2
 with comorbidities listed in 
the introduction. 
 
2.2 Recruitment, inclusion and exclusion criteria 
The study participants were recruited from the Obesity outpatient clinic, Haukeland 
University Hospital, Bergen, Norway, by retrieving information from the medical records of 
the participants. All measurements retrieved were collected in the period August 2013 through 
November 2014. 
 
When referred to the outpatient clinic of obesity, a broad informed consent for research is 
obtained which includes permission to retrieve information from the medical records in 
retrospect (Appendix II). 
 
When including patients for participation, the first anthropometrical data assessment 
completed was obtained and combined with the biochemical data closest in time. If the time 
between anthropometric and biochemical assessment exceeded 3 months, the patients were 
excluded. If the biochemical collection lacked some of the components needed for assessment 
of the MetS, the patients were excluded. One participant was excluded because blood sample 
was likely to not be taken in the fasting state. The inclusion is illustrated in Figure 2.  
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Figure 2 Patient inclusion flowchart. 
Abbreviations: AM, Anthropometric measurements; MetS, Metabolic syndrome. 
 
2.3 Assessment 
At enrollment at the outpatient clinic the patients undergo a physical examination as part of 
the commencement of the treatment of obesity. The examination included the following 
assessments: 
  
125 
with AM and 
bloodsample 
97 
with complete data 
collected 
96 
included in analyses 
89 
without blood sample 
within time-limit 
available (3 months) 
1 
blood sample not drawn 
in the fasting state 
214 
with anthropometric 
measurements 
28 
without MetS-criteria 
component or sitting 
height 
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2.3.1 Assessment of anthropometric measurements 
Height was measured to the nearest 1 mm with a stadiometer (Seca 240) with the participant 
standing with the feet together, and the heels, buttocks and shoulders touching the 
stadiometer. The participant should not wear shoes or socks, only light clothing. The head 
should be in a position with the lower edge of the eye socket in the same horizontal plane as 
the notch superior to the tragus of the ear. 
Sitting height was also measured to the nearest 1 mm with a stadiometer, but with the 
participant sitting on a chair which is 72.1 cm high. This value was later subtracted from the 
outcome. The sacrum and shoulder should touch the stadiometer and the head should be in the 
same position as when measuring height. 
WC was measured at the most narrow point between costae 10 and crista iliaca with a flexible 
non-elastic tape at the end of expiration. 
Body weight was measured to the nearest 0.1 kg using a calibrated scale (InBody 720) with 
the participant ideally only wearing underwear; however, nine participants were weighed 
wearing clothes. 
All measurements were done according to the recommended techniques described by 
Júlíusson et al. (74). 
BMI was calculated using weight in kilograms divided by the square of the height in meters. 
WHtR and WSHR were calculated by dividing WC by height and sitting height, respectively.  
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2.3.2 Assessment of blood pressure and pulse 
Blood pressure measurements and pulse were routinely assessed twice to be able to use the 
mean for analysis. When only one measurement was obtained this measurement was included 
with the means (two participants). Blood pressure measurements were in principle assessed by 
an automatic sphygmomanometer (Criticare 506 DN), but for three participants a manual 
control examination was assessed and the respective control data have been selected for 
analysis. Before measuring, the participant should be seated for at least five minutes, and an 
appropriate cuff size, covering about 2/3 of the upper arm, was used. 
The definition of hypertension in children is following the Guidelines from the National High 
Blood Pressure Education Program Working group (75). Blood pressure was divided into the 
following four stages, after adjusting for age, height and gender (Appendix III): 
 
Table 1 Classification of hypertension. 
Systolic or diastolic blood pressure:  Stage Category 
<90
th
 percentile Normal blood pressure 0 
90-<95
th
 percentile or 
>120/80 (yet <95
th
 percentile) 
Prehypertension 
1 
95
th
 – 5 mmHg above the 99th percentile Stage 1 (moderate hypertension) 2 
>99
th
 percentile + 5 mmHg Stage 2 (severe hypertension) 3 
 
2.3.3 Assessment of laboratory measurements 
At examination blood samples were requisitioned and the patients were encouraged to return 
for withdrawal of fasting blood samples at a later time. The following biochemical data were 
collected from fasting samples of serum, listed in the medical records: Glucose, HbA1c, CRP, 
ALAT, ASAT, gamma-GT, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides, insulin and insulin c-peptide. 
HOMA-IR was calculated as HOMA-IR = [s-glc (mmol/L) x s-insulin (mU/L) /22.5] (76). 
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2.4 Defining the metabolic syndrome 
The MetS was defined using the Cook’s definition (50) with the following cut-offs: 
 WC > 1.3 SDS, 
 Fasting glucose ≥ 6.1 mmol/L, 
 Triglycerides ≥ 1.24 mmol/L or HDL ≤ 1.03 mmol/L, 
 SBP or DBP ≥ 90th percentile, adjusted for height, age and gender. 
The MetS is present if three or more abnormalities exist. 
 
2.5 Statistical analyses and presentation of data 
Descriptive and explorative statistics were run to check for normality. All variables were 
normally distributed, except for insulin, insulin c-peptide, HOMA-IR and triglycerides, which 
were skewed. The statistical analyses are therefore run with these assumptions, using Pearson 
correlation for the normally distributed data, and Spearman correlation for the skewed data. 
However, for comparing means, student t-test was used for all variables, and not Mann-
Whitney as Mann-Whitney assumes equal distributions, and the student t-test is a very robust 
test, even for small samples. 
SDS for the new variable WSHR were compiled, using R, based on Norwegian growth charts 
from the Bergen Growth Study (77). 
All analyses were run using SDS for the anthropometric measurements as it makes the values 
comparable between age and gender.  
The prevalence of the MetS was calculated using frequency statistics, and as the prevalence is 
a proportion, the 95% confidence interval (CI) was calculated using the central limit theorem 
for binomial distribution with the following formula: 
CI = p̂ ± z √ (p̂(1- p̂)/n), where 
p̂ = prevalence 
n = number of participants 
z = 1.96. 
 
Simple analyses of linear regression were performed to see how the anthropometric 
measurements were related to the cardiometabolic biomarkers. Linear regression models were 
then adjusted for age and gender. The reason why the analyses are run with and without 
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adjusting for age and gender although using SDS is that there may be different risks for age 
and gender beyond what the SDS can adjust for. For instance boys and girls with the same 
IOTF BMI and different age may have a different risk of developing the MetS. 
Logistic regression models were performed when the outcomes were dichotomous, that is for 
the blood pressure levels (below or above the 90
th
 percentile) and liver transaminases as it 
would be irrelevant to see an association within the normal range for these parameters. Also 
for the presence of the MetS, logistic regression was used to see what anthropometric 
measurement predict the syndrome. The logistic regression models were run both with and 
without adjusting for age and gender. All descriptive data, correlations and regression models 
were performed using the Statistical Package for the Social Sciences (SPSS version 22 for 
Windows, Chicago, IL, USA). 
Akaike weights were calculated from the Akaike Information Criteria (AIC) from a 
multinomial regression model, adjusted for age and gender, using R (version 3.1.3 for 
Windows). 
Akaike weight is an alternative method for selecting the best approximating model in a set. 
When interpreting the AIC value, the absolute number is irrelevant; the important is the AIC 
values, in relation to each other and the difference between them. The best model will have 
the lowest AIC. The differences (Δ) between the top model and the other AIC values are 
calculated, and interpreted as follows: A model with a small difference (0-2) is plausible to 
have a substantial level of empirical support of the model, while a difference of 4-7 would 
have considerably less, and a difference of more than 10 would provide essentially no support 
(78). The relative likelihood is calculated as exp(-Δ/2), and the Akaike weight is the relative 
likelihood divided by the sum of all relative likelihoods which can be interpreted as the 
probability of the model being the best. 
The particular anthropometric measurement models were selected for Akaike information 
criteria because they theoretically should be able to contribute to the prediction of the MetS, 
the blood pressure values, and the transaminase values. 
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3 Results 
All of the included participants had all anthropometric measurements and the parameters 
required for defining the MetS available. However, for some of the metabolic parameters, a 
smaller sample was used (i.e. s-insulin, n=87; insulin c-peptide, n=85; total cholesterol, n=95; 
LDL, n=95; gGT, n=83; ALAT, n=89).  
The results include the presentation of descriptive statistics, prevalence of the MetS, 
correlation and regression models, and Akaike weights. 
 
3.1 Descriptive statistics 
Sample size, mean, standard deviation and range for age and the anthropometric 
measurements are presented in Table 2. Independent samples t-test indicated boys were 
significantly heavier, taller and had a higher sitting height than girls (all p-values <0.02), 
however no significant differences were found between the respective SDS. Boys had a 
significantly smaller WC SDS and WHtR SDS (p-value <0.01) than girls. 
 
Sample size, mean, standard deviation, median, 25
th
-75
th
 percentile and range for the 
biomarkers are presented in Table 5. Independent samples t-test indicated boys had 
significantly higher ALAT-levels than girls. 
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Table 2 Descriptive data on age and anthropometric measurements. 
  
Total (n=96) 
 
Boys (n=46) 
 
Girls (n=50) 
 
 
Variables Mean±SD Min-Max Mean±SD Min-Max Mean±SD Min-Max p-value* 
Age (years) 12.98±3.26 5.89-18.20 13.07±2.89 5.97-17.91 12.89±3.59 5.89-18.20  
Weight (kg) 87.5±27.1 29.4-137.3 94.7±27.3 36.1-137.3 80.9±25.5 29.4-129.0 0.010 
Weight SDS 3.17±0.81 -0.21-5.40 3.24±0.59 1.71-4.56 3.11±0.98 -0.20-5.40  
Height (cm) 159.6±16.9 115.3-186.6 165.1±17.2 117.0-186.6 154.6±15.0 115.0-179.0 <0.001 
Height SDS 0.48±1.25 -3.62-4.47 0.71±1.17 -2.20-4.47 0.26±1.30 -3.60-4.20  
Sitting height (cm) 84.8±8.1 66.0-101.5 86.9±8.3 66.0-101.5 83.0±7.5 66.1-94.7 0.020 
Sitting height SDS 0.81±1.07 -1.93-4.13 0.99±1.05 -1.73-4.13 0.64±1.08 -1.90-3.47  
WC (cm) 103.9±15.6 60.1-137.8 105.4±14.1 66.4-130.8 102.5±17.0 60.1-138.0  
WC SDS 3.12±0.58 1.68-4.74 2.85±0.31 1.79-3.47 3.36±0.67 1.68-4.74 <0.001 
BMI (kg/m2) 33.3±5.4 21.8-45.6 33.9±5.1 21.8-45.6 32.8±5.6 22.1-43.1  
BMI SDS 3.09±0.55 1.76-4.56 3.05±0.40 2.19-4.17 3.13±0.67 1.76-4.56  
WHtR 0.649±0.064 0.516-0.808 0.638±0.056 0.516-0.784 0.660±0.067 0.520-0.808  
WHtR SDS 3.06±0.41 1.82-3.96 2.95±0.35 1.96-3.54 3.16±0.45 1.82-3.96 0.010 
WSHR SDS 2.95±0.41 1.50-4.00 2.91±0.36 1.76-3.44 2.98±0.45 1.50-4.00  
*Differences between boys and girls, students t-test. 
Abbreviations: WC, waist circumference; BMI, Body Mass Index; WHtR, Waist-to-height-Ratio; WSHR, Waist-to-sitting height-Ratio 
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Descriptive data for the blood pressure values are shown in Table 3. Boys had a significantly 
higher SBP than girls, but for DBP there was no significant difference. 
 
Table 3 Descriptive data on blood pressure. 
Variables 
Total (n=96) Boys (n=46) Girls (n=50) 
Mean±SD 
Min-
Max 
Mean±SD 
Min-
Max 
Mean±SD 
Min-
Max 
SBP(mmHg) 125.4±13.7 90-163 128.4±14.1 93-163 122.6±12.9 90-151* 
DBP(mmHg) 73.8±9.6 57-99.5 74.6±9.2 57.5-98.5 73.1±10.1 57-99.5 
* Significant difference between boys and girls, students t-test (p=0.040) 
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure 
 
When adjusted for age, height and gender, most boys had SBP in the second category, 
between the 95
th
 and 99
th
 percentile, while most girls were in the first category, below the 90
th
 
percentile. For DBP, both boys and girls, most participants were in the first category, below 
the 90
th
 percentile. 
 
Table 4 Prevalence in the different blood pressure categories. 
Blood pressure 
category 
Total (n=96) Boys (n=46) Girls (n=50) 
SBP 
(%) 
DBP 
(%) 
SBP 
(%) 
DBP 
(%) 
SBP 
(%) 
DBP 
(%) 
0 (<90
th
 percentile) 29.2 66.7 23.9 60.9 34.0 72.0 
1 (90-95
th
 percentile) 26.0 16.7 28.3 21.7 24.0 12.0 
2 (95-99
th
 percentile) 31.3 13.5 34.8 15.2 28.0 12.0 
3 (>90
th
 percentile) 13.5 3.1 13.0 2.2 14.0 4.0 
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure 
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Table 5 Descriptive data on the biomarkers. 
 
 
 
Total Boys Girls 
Variables n 
Mean 
±SD 
Min-Max 
Med
ian 
25-75 
percentile 
n 
Mean 
±SD 
Min-Max 
Med
ian 
25-75p n 
Mean 
±SD 
Min-Max 
Med
ian 
25-75 
percentile 
Glucose 
(mmol/L) 
96 5.0 
±0.5 
4.1-7.1 5.0 4.6-5.2 46 5.0 
±0.4 
4.1-6.2 5.0 4.8-5.2 50 4.9 
±0.5 
4.2-7.1 4.9 4.6-5.2 
Insulin (mU/L)ᵟ 87 18.4 
±13.6 
2.0-73.7 15.4 10.4-21.2 46 18.8 
±13.9 
2.0-73.7 15.7 10.2-22.1 41 17.9 
±13.4 
2.0-66.8 15.4 10.4-20.4 
Insulin c-peptid 
(nmol/L)ᵟ 
85 1.0 
±0.6 
0.3-3.0 0.87 0.7-1.2 44 1.1 
±0.6 
0.3-3.0 0.9 0.6-1.3 41 1.0 
±0.5 
0.3-2.9 0.8 0.7-1.0 
HOMA-IRᵟ 87 4.2 
±3.4 
0.4-17.6 3.31 2.1-4.6 46 4.2 
±3.2 
0.4-16.4 3.3 2.1-5.0 41 4.1 
±3.6 
0.4-17.6 3.5 2.2-4.6 
TG (mmol/L)ᵟ 96 1.2 
±0.6 
0.3-2.6 1.05 0.8-1.6 46 1.3 
±0.5 
0.5-2.6 1.2 0.9-1.2 50 1.1 
±0.6 
0.3-2.4 0.9 0.7-1.5 
Tchol (mmol/L) 95 4.3 
±0.9 
2.3-6.6 4.3 3.7-4.8 45 4.3 
±0.8 
2.3-6.4 4.2 3.7-4.8 50 4.3 
±0.9 
2.5-6.6 4.3 3.7-4.8 
HDL-C (mmol/L) 96 1.2 
±0.3 
0.6-2.4 1.2 1.1-1.3 46 1.2 
±0.3 
0.6-1.9 1.2 1.0-1.3 50 1.3 
±0.3 
0.8-2.4 1.2 1.2-1.3 
LDL-C (mmol/L) 95 2.8 
±0.8 
0.6-5.2 2.8 2.3-3.3 46 2.8 
±0.8 
0.6-5.2 2.8 2.3-3.3 49 2.8 
±0.8 
1.2-4.9 2.8 2.3-3.3 
gammaGT (U/L) 83 20.9 
±10.7 
5.0-50.0 17.0 14.0-27.0 44 25.7 
±11.5 
8.0-50.0 23.5 16.3-32.8 39 15.5 
±6.4 
5.0-39.0 14.0 12.0-16.0 
ALAT (U/L) 89 30.6 
±22.5 
8.0-131 23.0 17.0-34.5 45 39.1 
±27.0 
11.0-131 27.0 20.0-56.5 44 21.8 
±11.8 
8.0-75.0 20.0 15.3-27.0* 
ᵟThe shaded variables were not normally distributed.  
*Difference between boys and girls, students t-test (p<0.001). 
Abbreviations:  HOMA-IR, Homeostatic model assessment of insulin resistance; TG, Triglycerides; Tchol, Total cholesterol; HDL-C, High-Density 
Lipoprotein cholesterol; LDL-C, Low-Density Lipoprotein Cholesterol; gammaGT, gamma-Glutamyl-Transferase; ALAT, Alanine Aminotransferase 
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3.2 Prevalence 
The prevalence of the MetS among obese children and adolescents in this sample as defined 
by Cook et al. (50) was 39.6% and the 95 % confidence interval was 29.8%-49.4%. 
 
Chi squared test revealed that there was no significant difference between the prevalence in 
boys (45.7%) and girls (34.0%) (χ2(1, N=96 =1.36, p=0.244).  
A figure presenting the prevalece of the number of components of the MetS for all 
participants, and for boys and girls seperately is described below. None of the participants had 
zero components. 
 
 
Figure 3 Subjects grouped according to the number of components of the metabolic syndrome 
they present with. 
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Frequency statistics for the determinants used to define the MetS showed that all of the 
participants had a WC SDS greater than 1.3, 77.1% had increased blood pressure, 45.8% had 
decreased HDL-cholesterol or increased triglyceride levels, and 2.1% had increased glucose-
levels as shown in the figure below: 
 
 
Figure 4 Prevalence of the different components of the metabolic syndrome. 
Abbreviations: WC, waist circumference; BP, blood pressure; Lipid, decreased HDL or 
increased triglycerides; Glc, fasting serum glucose 
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3.3 Correlations 
All anthropometric measurements were highly correlated with each other:  
Table 6 Pearson correlations for anthropometric measurements. 
Pearson Correlations 
  
 
BMI SDS WC SDS WHtR SDS WSHR SDS 
BMI SDS 
r 1       
sig.         
WC SDS 
r 0.776* 1     
sig. <0.001       
WHtR SDS 
r 0.779* 0.883* 1   
sig. <0.001 <0.001     
WSHR SDS 
r 0.684* 0.817* 0.916* 1 
sig. <0.001 <0.001 <0.001   
*p-value<0.001 
Abbreviations: BMI, Body Mass Index; WC, waist circumference; WHtR, Waist-to-height-
Ratio; WSHR, Waist-to-sitting height-Ratio 
 
 
WSHR SDS was correlated with the highest amount of biomarkers and was the only model 
significantly correlated to gGT. BMI SDS was correlated strongest to the blood pressure-
values. Age was also significantly correlated with several of the examined biomarkers, as 
shown in Table 7. 
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Table 7 Pearson and Spearman correlations for anthropometric measurements and blood pressure and biomarkers. 
  
Correlations 
  
SBP DBP glucose insulinᵟ c-peptideᵟ HOMA-IRᵟ triglyceridesᵟ cholesterol HDL LDL gGT 
Age 
r 0.299** 0.285** 0.188 0.416*** 0.485*** 0.410*** 0.257* 0.161 -0.223* 0.164 0.433*** 
sig 0.003 0.005 0.067 <0.001 <0.001 <0.001 0.012 0.119 0.029 0.113 <0.001 
Gender 
r 0.073 0.064 0.090 0.044 0.065 0.051 0.201 -0.032 -0.233* 0.013 0.477*** 
sig 0.482 0.539 0.383 0.683 0.556 0.637 0.050 0.755 0.022 0.898 <0.001 
BMI SDS 
r 0.347** 0.306** 0.163 0.319** 0.314** 0.316** 0.122 0.053 -0.141 0.044 0.165 
sig 0.001 0.002 0.112 0.003 0.003 0.003 0.236 0.607 0.170 0.675 0.136 
WC SDS 
r 0.257* 0.288** 0.094 0.191 0.252* 0.189 0.004 0.074 -0.082 0.061 0.054 
sig 0.012 0.005 0.362 0.076 0.020 0.079 0.965 0.478 0.425 0.557 0.627 
WHtR SDS 
r 0.289** 0.262** 0.057 0.156 0.188 0.151 0.014 0.035 -0.061 0.018 0.093 
sig 0.004 0.010 0.583 0.149 0.085 0.163 0.896 0.738 0.554 0.860 0.401 
WSHR SDS 
r 0.253* 0.256* 0.072 0.218* 0.244* 0.213* -0.006 0.023 -0.127 0.030 0.273* 
sig 0.013 0.012 0.487 0.042 0.025 0.048 0.956 0.823 0.216 0.776 0.012 
ᵟSpearman correlations 
*p<0.05 
**p<0.01 
***p<0.001 
Abbreviations: BMI, Body Mass Index; WC, waist circumference; WHtR, Waist-to-height-Ratio; WSHR, Waist-to-sitting height-Ratio; SBP, 
systolic blood pressure; DBP, Diastolic blood pressure; c-peptide, insulin-c-peptide; HOMA-IR, Homeostatic model assessment of insulin 
resistance; HDL, High-Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; gGT, gamma-Glutamyltransferase
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3.4 Regression 
Simple linear regression models on raw data showed that BMI SDS was significantly 
associated with serum insulin, insulin c-peptide, HOMA-IR (all p<0.01) and triglycerides 
(p=0.024). WC SDS and WHtR SDS were not associated with the selected biomarkers. 
WSHR SDS was significantly associated with c-peptide (p=0.039) and with gamma-gt 
(p=0.012). P-values below 0.050 are presented in bold. 
 
Table 8 Unadjusted linear regression for BMI SDS and biomarkers. 
BMI SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.20 0.12 -0.48 0.45 0.027 0.112 
Insulin  0.01 0.00 0.01 0.02 0.084 0.006 
HbA1c 0.14 0.18 -0.22 0.51 0.006 0.447 
HOMA-IR 0.05 0.02 0.02 0.08 0.098 0.003 
C-peptide 0.25 0.09 0.07 0.44 0.081 0.008 
TC 0.04 0.07 -0.10 0.17 0.003 0.607 
HDL -0.29 0.21 -0.71 0.13 0.020 0.170 
LDL 0.03 0.07 -0.11 0.17 0.002 0.675 
TG 0.22 0.10 0.03 0.42 0.053 0.024 
GammaGT 0.01 0.01 -0.01 0.02 0.027 0.136 
Abbreviations: HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic model assessment of 
insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total cholesterol; HDL, High-
Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; TG, 
triglyceride; GammaGT, Gamma-Glutamyltransferase 
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Table 9 Unadjusted linear regression for WC SDS and biomarkers. 
WC SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.12 0.13 -0.14 0.38 0.009 0.362 
Insulin  0.01 0.00 -0.00 0.02 0.031 0.100 
HbA1c 0.01 0.19 -0.37 0.40 0.000 0.949 
HOMA-IR 0.03 0.02 -0.00 0.06 0.038 0.070 
C-peptide 0.19 0.10 -0.00 0.39 0.044 0.053 
TC 0.05 0.07 -0.09 0.19 0.005 0.478 
HDL -0.18 0.22 -0.63 0.27 0.007 0.425 
LDL 0.04 0.07 -0.10 0.19 0.004 0.557 
TG 0.14 0.11 -0.07 0.34 0.017 0.203 
GammaGT 0.01 0.01 -0.01 0.02 0.003 0.627 
Abbreviations: HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic model assessment of 
insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total cholesterol; HDL, High-
Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; TG, 
triglyceride; GammaGT, Gamma-Glutamyltransferase 
 
Table 10 Unadjusted linear regression for WHtR SDS and biomarkers. 
WHtR SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.05 0.09 -0.14 0.24 0.003 0.583 
Insulin  0.00 0.00 -0.00 0.01 0.023 0.159 
HbA1c 0.12 0.14 -0.16 0.39 0.008 0.404 
HOMA-IR 0.02 0.01 -0.01 0.04 0.024 0.149 
C-peptide 0.12 0.07 -0.03 0.26 0.031 0.108 
TC 0.02 0.05 -0.08 0.12 0.001 0.738 
HDL -0.10 0.16 -0.41 0.22 0.004 0.554 
LDL 0.01 0.05 -0.09 0.11 0.000 0.860 
TG 0.07 0.08 -0.08 0.22 0.010 0.338 
GammaGT 0.00 0.00 -0.01 0.01 0.009 0.401 
Abbreviations: HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic model assessment of 
insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total cholesterol; HDL, High-
Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; TG, 
triglyceride; GammaGT, Gamma-Glutamyltransferase 
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Table 11 Unadjusted linear regression for WSHR SDS and biomarkers. 
WSHR SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.07 0.09 -0.12 0.25 0.005 0.487 
Insulin  0.01 0.00 0.00 0.01 0.040 0.063 
HbA1c 0.16 0.14 -0.11 0.43 0.015 0.239 
HOMA-IR 0.02 0.01 -0.00 0.04 0.038 0.072 
C-peptide 0.15 0.07 0.01 0.29 0.050 0.039 
TC 0.01 0.05 -0.09 0.11 0.001 0.823 
HDL -0.20 0.16 -0.51 0.12 0.016 0.216 
LDL 0.02 0.05 -0.09 0.12 0.001 0.776 
TG 0.08 0.07 -0.07 0.23 0.012 0.298 
GammaGT 0.01 0.00 0.00 0.02 0.075 0.012 
Abbreviations: HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic model assessment of 
insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total cholesterol; HDL, High-
Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; TG, 
triglyceride; GammaGT, Gamma-Glutamyltransferase 
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Scatter diagrams illustrating the significant results from unadjusted linear regression models 
are presented below: 
 
 
 
 
 
 
 
 
Figure 5 Scatterplots for linear regression models with p<0.05. 
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When adjusted for age and gender, linear regression models showed no significant association 
between the anthropometrics and the biomarkers from the blood samples (All p>0.05). 
 
Table 12 Linear regression for BMI SDS and biomarkers, adjusted for age and gender. 
BMI SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.09 0.09 -0.10 0.27 0.051 0.358 
Insulin  5.10 3.07 -1.02 11.20 0.138 0.101 
HbA1c 0.72 0.07 -0.06 0.20 0.047 0.273 
HOMA-IR 1.41 0.76 -0.10 2.92 0.153 0.066 
C-peptide 0.18 0.13 -0.07 0.44 0.162 0.152 
TC -0.05 0.18 -0.40 0.31 0.028 0.789 
HDL -0.04 0.05 -0.14 0.07 0.105 0.519 
LDL -0.06 0.18 -0.40 0.29 0.028 0.753 
TG 0.15 0.11 -0.07 0.38 0.118 0.181 
GammaGT -0.05 1.98 -3.99 3.88 0.401 0.979 
Abbreviations: BMI, Body Mass Index; HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic 
model assessment of insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total 
cholesterol; HDL, High-Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein 
Cholesterol; TG, triglyceride; GammaGT, Gamma-Glutamyltransferase 
 
Table 13 Linear regression for WC SDS and biomarkers, adjusted for age and gender. 
WC SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.06 0.10 -0.14 0.27 0.047 0.533 
Insulin  2.75 3.55 -4.32 9.82 0.116 0.441 
HbA1c 0.08 0.07 -0.06 0.22 0.049 0.243 
HOMA-IR 0.73 0.88 -1.02 2.48 0.125 0.410 
C-peptide 0.18 0.15 -0.11 0.47 0.156 0.225 
TC -0.03 0.19 -0.41 0.35 0.028 0.865 
HDL -0.07 0.06 -0.18 0.05 0.113 0.260 
LDL -0.01 0.19 -0.38 0.36 0.027 0.947 
TG 0.13 0.12 -0.11 0.08 0.112 0.280 
GammaGT 1.79 2.09 -2.36 5.95 0.407 0.393 
Abbreviations: HbA1c, Hemoglobin A1c; HOMA-IR, Homeostatic model assessment of 
insulin resistance; c-peptide, serum-insulin c-peptide; TC, Total cholesterol; HDL, High-
Density Lipoprotein cholesterol; LDL, Low-Density Lipoprotein Cholesterol; TG, 
triglyceride; GammaGT, Gamma-Glutamyltransferase 
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Table 14 Linear regression for WHtR SDS and biomarkers, adjusted for age and gender. 
WHtR SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.01 0.13 -0.24 0.26 0.043 0.944 
Insulin  2.59 4.19 -5.74 10.92 0.113 0.538 
HbA1c 0.14 0.87 -0.04 0.31 0.060 0.123 
HOMA-IR 0.58 1.04 -1.48 2.65 0.121 0.576 
C-peptide 0.14 0.17 -0.20 0.48 0.148 0.410 
TC -0.10 0.24 -0.57 0.38 0.029 0.687 
HDL -0.03 0.07 -0.17 0.12 0.102 0.688 
LDL -0.10 0.23 -0.56 0.10 0.029 0.660 
TG 0.06 0.15 -0.24 0.37 0.102 0.685 
GammaGT 0.95 2.67 -4.36 6.27 0.402 0.722 
Abbreviations: WHtR, Waist-to-Height-Ratio; HbA1c, Hemoglobin A1c; HOMA-IR, 
Homeostatic model assessment of insulin resistance; c-peptide, serum-insulin c-peptide; TC, 
Total cholesterol; HDL, High-Density Lipoprotein cholesterol; LDL, Low-Density 
Lipoprotein Cholesterol; TG, triglyceride; GammaGT, Gamma-Glutamyltransferase 
 
Table 15 Linear regression for WSHR SDS and biomarkers, adjusted for age and 
gender. 
WSHR SDS 
 
b SE 
95% c.i. 
lower 
95% c.i. 
upper 
R
2
 p-value 
Glucose 0.02 0.12 -0.22 0.26 0.042 0.871 
Insulin  4.45 4.02 -3.55 12.45 0.122 0.272 
HbA1c 0.12 0.08 -0.04 0.29 0.058 0.141 
HOMA-IR 0.99 1.00 -1.00 2.97 0.128 0.326 
C-peptide 0.22 0.17 -0.11 0.54 0.158 0.197 
TC -0.08 0.23 -0.54 0.37 0.029 0.723 
HDL -0.06 0.07 -0.19 0.08 0.107 0.429 
LDL -0.05 0.22 -0.49 0.38 0.027 0.808 
TG 0.05 0.15 -0.24 0.34 0.102 0.752 
GammaGT 4.32 2.58 -0.82 9.46 0.422 0.098 
Abbreviations: WSHR, Waist-to-sitting height-Ratio; HbA1c, Hemoglobin A1c; HOMA-IR, 
Homeostatic model assessment of insulin resistance; c-peptide, serum-insulin c-peptide; TC, 
Total cholesterol; HDL, High-Density Lipoprotein cholesterol; LDL, Low-Density 
Lipoprotein Cholesterol; TG, triglyceride; GammaGT, Gamma-Glutamyltransferase 
 
  
30 
 
Unadjusted binary logistic regression models showed BMI SDS was the only model to 
significantly predict the MetS, with an OR of 3.62. 
Table 16 Unadjusted logistic regression for BMI SDS. 
BMI SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.91 -0.09 (0.50) 0.34 2.43 0.001 0.854 
SBP 5.21 1.65 (0.53) 1.86 14.59 0.173 0.002 
DBP 2.63 0.97 (0.42) 1.15 6.02 0.079 0.023 
MetS 3.62 1.29 (0.44) 1.53 8.60 0.133 0.004 
Abbreviations: BMI, Body Mass Index; ALAT, Alanine Aminotransferase; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
 
Table 17 Unadjusted logistic regression for WC SDS. 
WC SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.63 -0.47 (0.49) 0.24 1.64 0.010 0.341 
SBP 2.92 1.07 (0.45) 1.21 7.08 0.093 0.018 
DBP 2.33 0.85 (0.40) 1.07 5.09 0.069 0.033 
MetS 1.92 0.65 (0.38) 0.92 4.02 0.044 0.083 
Abbreviations: WC, Waist circumference; ALAT, Alanine Aminotransferase; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
 
Table 18 Unadjusted logistic regression for WHtR SDS. 
WHtR SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.61 -0.49 (0.65) 0.17 2.21 0.010 0.455 
SBP 5.47 1.70 (0.61) 1.66 18.03 0.126 0.005 
DBP 3.00 1.10 (0.58) 0.96 9.30 0.055 0.058 
MetS 2.39 0.87 (0.54) 0.83 6.88 0.038 0.107 
Abbreviations: WHtR, Waist-to-Height-Ratio; ALAT, Alanine Aminotransferase; SBP, 
Systolic blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
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Table 19 Unadjusted logistic regression for WSHR SDS. 
WSHR SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 1.57 0.45 (0.71) 0.39 6.29 0.007 0.526 
SBP 5.48 1.70 (0.61) 1.66 18.11 0.127 0.005 
DBP 3.46 1.24 (0.63) 1.02 11.77 0.064 0.047 
MetS 2.11 0.75 (0.55) 0.72 6.18 0.028 0.174 
Abbreviations: WSHR, Waist-to-sitting height-Ratio; ALAT, Alanine Aminotransferase; 
SBP, Systolic blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
 
Binary logistic regression adjusted for age and gender also showed that BMI SDS was the 
only model significantly related to the MetS (p=0.03), with an OR of 2.96. BMI SDS, WHtR 
SDS and WSHR SDS were significantly associated with SBP, while WC SDS had a p-value 
of 0.054. WC SDS was the only model significantly associated with DBP (p=0.031). 
Table 20 Logistic regression for BMI SDS, adjusted for age and gender. 
BMI SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.54 -0.62 (0.74) 0.13 2.30 0.357 0.405 
SBP 3.37 1.22 (0.55) 1.15 9.86 0.24 0.026 
DBP 2.13 0.76 (0.49) 0.82 5.56 0.139 0.123 
MetS 2.96 1.08 (0.05) 1.11 7.86 0.193 0.030 
Abbreviations: BMI, Body Mass Index; ALAT, Alanine Aminotransferase; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome.  
32 
 
Table 21 Logistic regression for WC SDS, adjusted for age and gender. 
WC SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.73 -0.32 (0.87) 0.13 4.02 0.349 0.716 
SBP 2.89 1.06 (0.55) 0.98 8.50 0.222 0.054 
DBP 4.07 1.40 (0.65) 1.14 14.57 0.178 0.031 
MetS 2.15 0.77 (0.55) 0.73 6.33 0.155 0.166 
Abbreviations: WC, Waist circumference; ALAT, Alanine Aminotransferase; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
 
Table 22 Logistic regression for WHtR SDS, adjusted for age and gender. 
WHtR SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 0.56 -0.59 (0.96) 0.08 3.66 0.353 0.541 
SBP 4.38 1.48 (0.67) 1.18 16.28 0.236 0.027 
DBP 3.02 1.11 (0.70) 0.77 11.78 0.142 0.112 
MetS 1.99 0.69 (0.64) 0.56 7.00 0.144 0.286 
Abbreviations: WHtR, Waist-to-Height-Ratio; ALAT, Alanine Aminotransferase; SBP, 
Systolic blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
 
Table 23 Logistic regression for WSHR SDS, adjusted for age and gender. 
WSHR SDS 
 
OR b (SE) 
95% c.i. 
lower 
95% c.i. 
upper 
Nagelkerke 
R
2
 
p-value 
ALAT 1.01 0.01 (0.98) 0.15 6.81 0.347 0.993 
SBP 4.04 1.40 (0.64) 1.15 14.17 0.235 0.029 
DBP 2.75 1.01 (0.68) 0.73 10.37 0.138 0.136 
MetS 1.44 0.36 (0.61) 0.43 4.76 0.133 0.555 
Abbreviations: WSHR, Waist-to-sitting height-Ratio; ALAT, Alanine Aminotransferase; 
SBP, Systolic blood pressure; DBP, Diastolic blood pressure; MetS, Metabolic syndrome. 
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3.5 Akaike Information Criteria 
Akaike information criteria used to compare the models selected for predicting the MetS 
showed by Akaike weights that BMI SDS has the highest probability of being the best model 
(69.5%). The differences in AIC between BMI SDS and the other models show that WC SDS 
was somewhat less likely to provide a similar level of empirical support of the model, and the 
WHtR SDS and WSHR SDS were considerably less likely to provide a similar level of 
empirical support of the model. 
 
Table 24 Model fit for predicting the metabolic syndrome. 
Model AIC Δ 
Relative 
likelihood 
Akaike weight 
BMI SDS 122.12 0 1 0.695 
WC SDS 125.2 3.08 0.214 0.149 
WHtR SDS 126.12 4.00 0.135 0.094 
WSHR SDS 126.94 4.82 0.090 0.062 
Abbreviations: WC, waist circumference; BMI, Body Mass Index; WHtR, Waist-to-height-
Ratio; WSHR, Waist-to-sitting height-Ratio; AIC, Akaike’s information criterion. 
 
For the prediction of SBP, the differences in AIC values were below two, which tells us all 
measurements were plausible to have a substantial level of empirical support of the model. 
 
Table 25 Model fit for predicting elevated systolic blood pressure. 
Model AIC Δ 
Relative 
likelihood 
Akaike weight 
BMI SDS 106.22 0 1 0.317 
WHtR SDS 106.54 0.32 0.852 0.270 
WSHR SDS 106.62 0.40 0.819 0.260 
WC SDS 107.69 1.47 0.480 0.152 
Abbreviations: WC, waist circumference; BMI, Body Mass Index; WHtR, Waist-to-height-
Ratio; WSHR, Waist-to-sitting height-Ratio; AIC, Akaike’s information criterion. 
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For the prediction of DBP, WC SDS had the highest probability of being the best model 
(60.4%), and the other anthropometric measurements were somewhat less likely to provide a 
similar level of empirical support. 
Table 26 Model fit for predicting elevated diastolic blood pressure. 
Model AIC Δ 
Relative 
likelihood 
Akaike weight 
WC SDS 117.01 0 1 0.604 
WHtR SDS 119.89 2.88 0.237 0.143 
BMI SDS 120.08 3.07 0.215 0.130 
WSHR SDS 120.19 3.18 0.204 0.123 
Abbreviations: WC, waist circumference; BMI, Body Mass Index; WHtR, Waist-to-height-
Ratio; WSHR, Waist-to-sitting height-Ratio; AIC, Akaike’s information criterion. 
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4 Discussion 
4.1 Discussion of the results 
The first aim of this thesis was to determine the prevalence of the MetS among obese children 
and adolescents at the Obesity outpatient clinic at Haukeland University Hospital. 
The second aim was to determine whether the SDS for the anthropometrical measurements 
WC, WHtR, and WSHR predict cardiometabolic risk factors (insulin resistance, altered low 
density lipoprotein cholesterol, total cholesterol, triglycerides, high density lipoprotein 
cholesterol, and liver test (ALAT, gGT) or the MetS as defined by Cook et al. (50)) better 
than BMI SDS in overweight and obese children and adolescents at the Obesity outpatient 
clinic at Haukeland University Hospital. 
First I will discuss the results regarding the prevalence of the MetS, and then the different 
ways of assessing associations between anthropometric measurements and cardiometabolic 
risk factors. Further I will consider methodological strengths and limitations of this study, 
followed by the conclusions and implications for further research. 
4.1.1 Prevalence 
The prevalence of the MetS in this group of obese children and adolescents was 39.6 %. 
It seems there is little similarity among other Western reports: Cook et al. (50) found a 
prevalence of the MetS of 28.7% in adolescents with a BMI ≥95th percentile in the United 
States. A Spanish study (79), using the same definition on children and adolescents with an 
IOTF BMI >30 kg/m
2
 reported a prevalence of the MetS of 29.9%, and a Finnish study (80) 
on 17-year olds with an IOTF BMI >30 kg/m
2
 found the prevalence of the MetS based on 
ATP III criteria to be 36.7 % and 30.3% for boys and girls, respectively. 
An article from the ‘Oslo Adiposity Intervention Study’ (81) investigated the prevalence of 
the MetS in Norwegian children and adolescents compared with immigrants, all with an IOTF 
BMI>30 kg/m
2
, also using the Cook’s definition. They found the prevalence to be 30.0% in 
those with a Norwegian origin, and 50.0% for those with Middle Eastern and South Asian 
Origin. 
Another study conducted by laFortuna et al. (82) on adolescents with a BMI ≥97th percentile 
found a prevalence of the MetS of 23.3% among Italian adolescents and 40.4% among 
German adolescents, using the criteria proposed by the International Diabetes Federation 
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(IDF) (83). A Danish study (84) on adolescents with an IOTF BMI > 30 kg/m
2
 also applied 
the IDF criteria and found a prevalence of 14.0%.  
The varying results in the studies substantiate a perception that there is little consensus on the 
prevalence of the MetS among Western countries. It is likely that the use of different criteria 
for defining the MetS, as well as different inclusion criteria will lead to different prevalences, 
as the prevalence of the MetS  has been proposed to depend strongly on the parameters 
chosen and their respective cut-off points (85), and as the risk of cardiometabolic alterations 
increase with an increasing BMI (86). However, there can also be other causes of variation, 
for instance methodological differences. 
The majority of the studies used for comparison have a lower prevalence than the one 
presented in this thesis. It is likely that this is due to the fact that several of the studies include 
children and adolescents with a lower BMI than ours, as the inclusion criteria for the Obesity 
outpatient clinic is having an IOTF BMI above 35 kg/m
2
. Also, for the report from the US, 
data from the NHANES survey in 1988-1994 was used, and it is likely that the prevalence in 
this age-group would be higher today as secular trends suggest an increase in obesity and 
DMT2 over the last years (50). 
Of the presented studies, the Spanish is the only one to include children younger than 12 years 
of age. As the presence of the MetS is highly correlated with age, different age-ranges in the 
studies make comparison somewhat difficult. Less is known of the prevalence of the MetS in 
younger children. It is also a drawback that the Danish study only included 51 participants.  
Another reason why our results are difficult to compare with other studies is the lack of 
assessment of ethnicity. It is probable that a quite large proportion of our study sample has an 
ethnicity other than Norwegian, as the ‘Oslo Adiposity Intervention Study’ which has a 
similar mission as the Obesity outpatient clinic in Bergen reported only 40.4% of their treated 
patients to be Norwegian. And as the MetS seems to be more frequent in immigrants than 
Norwegians (81) this can also explain the high prevalence in our study. 
While the prevalence of hypertension, altered lipid concentrations, and increased WC SDS are 
all quite high, the results of this thesis present a relatively low prevalence of hyperglycemia, 
measured by fasting glucose. This has been reported in other studies as well (79, 82), and 
hyperglycemia seems to be a less common component of the MetS in children compared with 
adults. This is strange as the insulin resistance is thought to be a significant contributor to the 
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development of the metabolic phenotype (54). However, a possible explanation can be that 
the insulin resistance has not manifested yet as the participants are rather young, or due to the 
fact that fasting insulin and glucose poorly describes the insulin-resistant state in children, 
compared with an oral glucose tolerance test which is considered the gold standard, although 
it has limitations for screening large-scale populations (87). 
4.1.2 Predictive value of anthropometric measurements 
Although some associations were significant in the correlation and unadjusted linear 
regression models, none were significant after adjusting for age and gender. Further, logistic 
regression showed the MetS was significantly related to BMI SDS, SBP was significantly 
related to all anthropometric measurements, and DBP was significantly related to BMI SDS, 
WC SDS and WSHR SDS when unadjusted, but only with WC SDS when adjusted for age 
and gender. BMI SDS was the best prediction model for the MetS and SBP, and WC SDS 
was the best for DBP, as they had the highest Akaike weights. 
It is of great importance to take into consideration that even though some of the correlations 
were statistically significant, they do not substantiate any causality, meaning that these results 
are not able to report any cause-and-effect relationship and we are therefore not able to imply 
whether an increased BMI SDS or WSHR SDS will cause altered transaminase-levels or 
cardiovascular risk. 
In the unadjusted linear regression models, the associations that are statistically significant all 
have a low r
2
 that vary between 0.05-0.10. This tells us none of the associations are 
particularly tight, and that a rather small proportion of the variance in the biomarkers is 
explained by the anthropometric models.  
The adjusted linear regression models showed no significant relation between the biomarkers 
and the anthropometric measurements.  It has previously been described that anthropometric 
measurements are not associated with fasting plasma glucose (88, 89), however, the 
respective studies showed associations with insulin and HOMA-IR, which is different from 
the presented results. Other studies are further in disagreement with the result of this thesis: 
Androutsos et al. found several cardiovascular risk factors to be associated with BMI, WC 
and WHtR (90). BMI and WHtR has also been reported to detect cardiometabolic 
disturbances in the Bogalusa Heart Study (91), and, in Australian children, Denney-Wilson et 
al. found associations between BMI and WHtR and insulin levels (92). Also in German 
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children anthropometrics are considered to be valuable for cardiovascular risk assessment 
(93).  
A drawback for using the presented studies as comparison is that all have investigated the 
associations in children with a broad range of BMI, whilst our study sample only include 
obese children. However, Bluher et al. (94) also found several cardiovascular risk factors 
(HDL, HOMA-IR, ALAT, and gGT) to be significantly correlated with BMI, WC, and WHtR 
in a group of overweight children, which contradict our results.  
The fact that this study group represents a marginal segment of the weight range is likely to be 
the reason why both correlation and regression analyses shows no association between WC 
and the cardiometabolic risk factors. This finding is particularly surprising, as other 
researchers have concluded that there is substantial evidence that WC is significantly 
associated with obesity-related morbidity, based on similar biomarkers as the ones presented 
in this thesis, and that WC should be used to identify children at risk (95). As a small variance 
in weight will make correlations hard to assess, it is plausible to believe that stronger 
associations would be present for several measurements if the study sample included children 
of all weight categories. This is further supported by Morandi et al. who also investigated 
associations between anthropometrical measurements and metabolic impairments in obese 
children, and concluded that anthropometrical measurements should not be used as a 
screening tool in the clinical setting to assess metabolic risk, as the predictive value is not 
satisfactory (96).  
The logistic regression analyses show that an increase of one standard deviation in BMI SDS 
gives 3.62 higher odds of having the MetS. However, the Nagelkerke squared r was 0.13, and 
again this underpins the fact that the MetS is accounted for by anthropometric measurements 
in a small degree. Also, the precise odds ratio is not of great importance as the confidence 
intervals are rather wide. The Akaike table nevertheless shows there was a 69.5% probability 
that BMI SDS was the best predictor for the MetS among the selected models. The fact that 
the other anthropometric models were less likely to provide a similar level of empirical 
support of the model is in accordance with the results from the logistic regression models, as 
BMI SDS was the only measurement significantly associated with the MetS. However, a low 
Akaike weight does not imply the model has no support in the data, only that the other models 
have more support. 
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For the SBP, the Nagelkerke squared r is ranging from 0.22-0.24 which implies that a greater 
degree of variation in blood pressure can be explained by the variation in anthropometric 
measurements. This is supported by other researchers who have found that anthropometric 
measurements are associated with and can predict SBP (90, 94, 97, 98). Also, for the 
prediction of SBP, the Akaike weights are more similar, ranging between 15-32%. BMI SDS 
was the best prediction model, and WC SDS the worst, but there was little difference between 
all. This is also in accordance with the results from the logistic regression models, as all 
anthropometric measurements were significantly associated with SBP except for WC SDS, 
which was borderline significant (p=0.054).  
Regarding DBP, WC SDS was more clearly a better predictor with an Akaike weight of 
60.4%. The AIC difference substantiates the other models are somewhat less likely to provide 
a similar level of support of the model. Again, the results from the Akaike weight are 
congruent with the result from the logistic regression as WC SDS was the only measurement 
significantly associated with the DBP. The findings on DBP are in accordance with what 
other researchers have found (90, 94, 97). 
Because WC previously has been shown to be a good predictor, other researchers have 
considered the question of whether it would be beneficial to combine BMI and WC. This is 
supported by Katzmanzyk et al. (98), and by Janssen et al. (97), and has been recommended 
in the clinical setting, as a high WC gives a higher health risk than a low WC across the same 
BMI category in adults (99). On the other hand, as the investigated anthropometric 
measurements in this thesis are so highly correlated with each other, as shown in Table 3, the 
effect of multicollinearity is reason to not pair the variables in statistical analyses for 
adjustment. Also, as the measurements based on WC SDS seem to contribute to such a small 
extent in this thesis, there is little reason to recommend WC as a complimentary measurement 
to BMI for predicting cardiometabolic risk. This account only for this group of obese children 
and adolescents, of course, as other ranges of BMI may provide different results. 
 
4.2 Methodological strengths and limitations 
Due to the retrospective collection method and the fact that the aim of this thesis not was 
ready when the assessment of data was conducted, the following methodological limitations 
were not predicted. 
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Pubertal stage has not been assessed or been accounted for in the medical records. As 
anthropometrics are influenced by pubertal stage in terms of that body composition changes 
dramatically during puberty, both level of body fatness and fat distribution may be stronger 
related to pubertal stage, rather than age. Therefore, the lack of this variable is a major 
setback.  
Although the patients are told to do the blood sampling in the fasting state, there is no control 
of whether they actually do so. As a blood sample of triglycerides will be dramatically higher 
if not taken in the fasting state, this may lead to a higher prevalence of the MetS than what is 
the actual case. This can also give misleading results regarding correlations and regression 
models, if the patients assumed to have increased insulin-, glucose-, or triglyceride levels are 
actually within the normal range, but have altered values because they have eaten before 
blood sampling. 
Another factor very likely to affect both body composition and biomarkers is ethnicity, which 
neither was assessed in a sufficient number of patients to be able to use for the analyses. As 
shown previously, ethnicity may affect cardiometabolic alterations investigated in this thesis, 
and can be a reason why the prevalence for the MetS is high. 
Nine of the participants were weighed with clothes on, and in retrospect we were not able to 
adjust for this because the collection method did not assess how much clothes they wore or 
how much weight should be subtracted. 
Moreover, blood samples of C-reactive protein were not assessed in enough patients to use the 
variable for statistics. It would be informative to collect these data, as acute phase proteins 
such as CRP reflect an inflammatory state which is thought to affect the development of the 
MetS (100). 
A positive feature regarding the assessment is that the documentation in the medical records 
at the Obesity outpatient clinic now is systematized in a better fashion as a result of this, 
which will make future research based on pre-collected data easier. 
The age range in this group can be considered a strength, as it is one of few studies that has 
included children below the age of ten years. On the other hand, including the youngest 
patients makes it hard to implement the IDF criteria for the MetS, which leads to some 
difficulties in comparing the prevalence of the MetS with other studies. 
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Another strength of this study is that it is one of few to investigate the predictive value of 
anthropometrical measurements in obese children and adolescents. 
Furthermore, there are some general drawbacks with anthropometric measurements affecting 
precision and accuracy, such as a non-standardized methodology and measurement 
discrepancies between methods (101). Despite the fact that the clinic uses guidelines for 
assessment, other studies may use other guidelines and direct comparisons are perhaps not 
based on the exact same measurement. Also, some interpersonal variation can be expected for 
measurements carried out at the clinic. 
As all anthropometric measurements have been converted to SDS, blood pressure 
measurements are adjusted for height, age and gender, and the MetS is defined using cutoffs 
based on percentiles in order to make comparison across age possible, these variables are 
already adjusted, and adjusting again in the regression models can be considered an “over-
adjustment”. The biomarkers on the other hand, are not adjusted, which makes a second 
adjustment necessary. It is also plausible that a second adjustment is necessary to correct for 
associations with age and gender which are not accounted for by the SDS. 
 
4.3 Conclusions 
4.3.1 Prevalence 
We hypothesized that the prevalence of the MetS would be similar to other European 
countries. Based on the presented literature, a prevalence of the MetS close to 40% in our 
sample is relatively high compared with what others have found, although one must take in to 
consideration that comparison is difficult without standardized international criteria. 
The high prevalence nevertheless underlines the importance of screening for cardiometabolic 
risk factors and providing good treatment for this group of patients with severe obesity. 
Moreover, the disputed literature on prevalence in different countries underlines the need for 
consensus on an international definition of the MetS in children, which also has been 
proposed by Ford et al. (52). 
4.3.2 Predictive value of anthropometric measurements 
We hypothesized that anthropometric measures can be a valuable predictor for the 
cardiometabolic risk factors. 
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Anthropometric measurements are probably not the main factor affecting the presence of the 
cardiovascular risk factors in this group of obese children and adolescents, except for the 
prediction of SBP, which is associated with several anthropometric measurements, and 
probably best explained by BMI SDS. 
One can hypothesize that because all of our participants are obese, other factors, such as a 
genetic predisposition, or other underlying causes, constitute who develops the MetS and who 
does not, and that there is a distinction between normal and overweight children and 
adolescents and those who are obese for the predictive value of anthropometric 
measurements. This thesis argues that for obese children, anthropometrical measurements 
have a rather low predictive value. 
Nevertheless, it is possible that the tendencies in the unadjusted analyses can be explained by 
differences in age and gender, and that the adjusted results therefore would become clearer 
with a greater dataset.  
The results showed that BMI SDS is the best predictor among the models selected as it had 
the lowest AIC, and it remains a valuable predictor for SBP. 
 
4.4 Further research 
For determining the prevalence of the MetS in obese children and adolescents further studies 
including assessment of ethnicity are needed. 
Although we did not find the WSHR SDS to improve the prediction of cardiometabolic 
disturbances beyond BMI SDS, there may still be other indexes including sitting height which 
can have a better predictive value. For instance it would be very interesting to investigate the 
weight-to-sitting height-ratio, or weight/(sitting height)
2
 as they would be more similar to the 
BMI. 
It would also be interesting to look for the predictive value of the anthropometric 
measurements in a sample of participants with a broader weight range, including normal 
weight children and adolescents, as it seems rather few of the articles used for comparison are 
based on a study sample with the inclusion criteria of an IOTF BMI >35 kg/m
2
. This thesis 
does not uncover whether the WSHR has a predictive value of metabolic changes in a sample 
with a wider weight range. 
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 Besøksadresse: Armauer Hansens hus, BERGEN 
Postadresse: Helse Bergen HF, Haukeland universitetssjukehus, 5021 Bergen 
Telefon: 05300 – E-post: postmottak@helse-bergen.no – Org. nr.: 983974724 
6.1  Appendix I: Data Protection Official 
 
       
 
 
Petur Benedikt Juliusson  
Haukeland universitetssjukehus  
Barneklinikken  
petur.benedikt.juliusson@helse-bergen.no 
 
 
Deres ref:  Vår ref:  Saksbehandler  BERGEN,  
 2014/21567  Øystein Svindland, 
tlf. 55975558  
06.11.2014  
 
 
Kvalitetssikring: «Beyond BMI» - tilråding  
 
Viser til innsendt melding om behandling av personopplysninger / helseopplysninger. Det 
følgende er en formell tilråding fra personvernombudet. Forutsetningene nedenfor må være 
oppfylt før innsamlingen av opplysningene / databehandlingen kan begynne.  
 
Prosjektet utgår fra Medisinsk avdeling og vil også bli benyttet i en mastergradsoppgave. 
Personvernombudet har vurdert det til at den planlagte databehandlingen faller inn under 
helsepersonelloven § 26: Den som yter helsehjelp, kan gi opplysninger til virksomhetens ledelse 
når dette er nødvendig for å kunne gi helsehjelp, eller for internkontroll og kvalitetssikring av 
tjenesten. Opplysningene skal så langt det er mulig, gis uten individualiserende kjennetegn.  
 
Personvernombudet tilrår at kvalitetsprosjektet gjennomføres under forutsetning av følgende:  
 
1. Behandling av helse- og personopplysningene skjer i samsvar med og innenfor det formål som 
er oppgitt i meldingen.  
2. Tilgangen til registeret skjer i overensstemmelse med taushetspliktbestemmelsene. Evt. 
prosjektmedarbeidere som ikke er ansatt i Helse Bergen HF må underskrive en såkalt ikke-ansatt-
avtale (se mal i forskningsrutinene) samt underskrive taushetsplikterklæring før de kan få tilgang 
til personopplysninger / helseopplysninger.  
3. Personidentifiserende data lagres avidentifisert utelukkende på helseforetakets Kvalitetsserver. 
For å få tildelt plass på Kvalitetsserveren må saksnummer på denne godkjenningen (under Vår 
ref) fylles ut i søknadsskjemaet og selve tilrådingsbrevet må også legges ved. 
Søknadsskjema finnes på:  
Helse Bergen Innsiden –Personvernombudet for Helse Bergen  
Annen elektronisk lagringsform forutsetter gjennomføring av en risikovurdering som må 
godkjennes av personvernombudet.  
4. Kryssliste som kobler avidentifiserte data med personopplysninger lagres enten elektronisk på 
tildelt område på Kvalitetsserveren eller nedlåst på prosjektleders kontor.  
5. Data slettes eller anonymiseres (ved at krysslisten slettes) 31.05.2020. Når formålet med 
registeret er oppfylt sendes melding om bekreftet sletting til personvernombudet 
 Besøksadresse: Armauer Hansens hus, BERGEN 
Postadresse: Helse Bergen HF, Haukeland universitetssjukehus, 5021 Bergen 
Telefon: 05300 – E-post: postmottak@helse-bergen.no – Org. nr.: 983974724 
6. Dersom det senere blir aktuelt å forske på det innsamlede materialet, må det søkes om 
godkjenning fra REK før forskningen starter.  
7. Dersom formålet eller databehandlingen endres må personvernombudet informeres om dette.  
 
 
 
Vennlig hilsen  
 
Øystein Svindland  
Personvernombud 
 
 
Kopi til:  
Lars Birger Nesje  
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6.2 Appendix II:  Informed consent 
Forespørsel om samtykke til forskning innen: ”Til normal vekt” – 
Behandlingsopplegg for sykelig overvekt, Barneklinikken, 
Haukeland Universitetssykehus 
 
Bakgrunn og hensikt 
Forskning på helseopplysninger relatert til pasienters diagnose, behandling og prognose er 
avgjørende for å sikre befolkningen en høy kvalitet på helsetjenestetilbudet. Ved Helse Bergen 
HF/Haukeland universitetssykehus arbeider vi kontinuerlig med å oppnå ny kunnskap om 
barneovervekt. For å kunne utføre denne forskningen, er vi avhengig av pasientenes samtykke.  
 
Samtykkets omfang og dine rettigheter 
Ved å signere samtykkeerklæringen aksepterer du at opplysninger og eventuelt prøvemateriale kan 
benyttes til forskning innen barneovervekt. I tillegg kan du bli spurt om å besvare spørreskjemaer og 
delta på oppfølgingstiltak for å samle inn ytterligere opplysninger. Vi vil også innhente relevante 
opplysninger om deg fra andre offentlige helseregistre ved behov. 
 
Eventuelle prøver og informasjonen som registreres om deg, vil bli behandlet konfidensielt og bli 
brukt til forskning på barneovervekt. Alle opplysningene vil bli behandlet uten navn og 
fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til dine 
opplysninger og prøver gjennom en navneliste. Det vil ikke være mulig å identifisere deg i 
forskningsresultatene når disse publiseres.  
 
Du kan til enhver tid få innsyn i hvilke opplysninger som er registrert om deg. Du har videre rett til å 
få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du trekker tilbake samtykket, 
kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre opplysningene allerede er 
inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Vi gjør oppmerksom på at opplysninger kan utleveres til samarbeidende forskere ved foretakene i 
Helse Vest og Universitetet i Bergen. Enhver utlevering av opplysninger til samarbeidende forskere vil 
bli lagt frem for Regional Etisk Komité (REK). 
Ytterligere informasjon 
Har du spørsmål tilknyttet forskningsvirksomheten, kontakt Pétur B. Júlíusson, Barneklinikken, 
Haukeland Universitetssykehus, petur.juliusson@med.uib.no, telefon 55975200. 
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Skjema for samtykke til forskning (Skannes til DIPS) 
- Voksne over 16 år 
 
Forskningsområde 
”Til normal vekt” – Behandlingsopplegg for sykelig overvekt, Barneklinikken, 
Haukeland Universitetssykehus 
Prosjektnummer 
177286 
Prosjektleders navn 
 
Pétur B. Júlíusson 
Klinikk/avdeling 
Barneklinikken, Haukeland 
Universitetssykehus 
All forskningsdeltakelse er frivillig. Dersom du ønsker å delta, undertegner du denne 
samtykkeerklæringen. Om du nå sier ja til å delta, kan du senere når som helst og uten å oppgi noen 
grunn, trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere 
ønsker å trekke deg eller har spørsmål om forskningen, kan du kontakte prosjektleder.  
 
 
Jeg er villig til at prøver og opplysninger om meg brukes i forskning på barneovervekt 
 
Navn med blokkbokstaver 
 
 
 
Fødselsnummer (11 siffer) 
 
Dato 
 
 
 
Underskrift 
 
Fylles ut av representant for forskningsområdet 
 
Jeg bekrefter å ha gitt informasjon om forskningsområdet: 
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Dato 
 
 
 
Underskrift Brukerkode (4-tegnskode) 
 
Eventuelle kommentarer: 
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Skjema for samtykke til forskning (Skannes til DIPS) 
- Ungdom mellom 12 og 16 år 
 
Forskningsområde 
”Til normal vekt” – Behandlingsopplegg for sykelig overvekt, Barneklinikken, 
Haukeland Universitetssykehus 
Prosjektnummer 
177286 
Prosjektleders navn 
 
Pétur B. Júlíusson 
Klinikk/avdeling 
Barneklinikken, Haukeland 
Universitetssykehus 
All forskningsdeltakelse er frivillig. Dersom du ønsker å delta, undertegner du denne 
samtykkeerklæringen. Om du nå sier ja til å delta, kan du senere når som helst og uten å oppgi noen 
grunn, trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere 
ønsker å trekke deg eller har spørsmål om forskningen, kan du kontakte prosjektleder. 
 
 
Jeg er villig til at prøver og opplysninger om meg brukes i forskning innen på barneovervekt 
 
Navn med blokkbokstaver 
 
 
 
Fødselsnummer (11 siffer) 
 
Dato 
 
 
 
Underskrift 
 
Helse Bergen ønsker at foresatte skal være informert og samtykke til deltakelse i forskning for 
ungdom over 12 år, med mindre pasienten av forhold som bør respekteres ønsker noe annet. 
 
Dato 
 
Underskrift Rolle (mor/far/verge) 
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Fylles ut av representant for forskningsområdet 
 
Jeg bekrefter å ha gitt informasjon om forskningsområdet: 
 
Dato 
 
 
 
Underskrift Brukerkode (4-tegnskode) 
 
Eventuelle kommentarer: 
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Skjema for samtykke til forskning (Skannes til DIPS) 
- Barn under 12 år 
 
Forskningsområde 
”Til normal vekt” – Behandlingsopplegg for sykelig overvekt, Barneklinikken, 
Haukeland Universitetssykehus 
Prosjektnummer 
177286 
Prosjektleders navn 
 
Pétur B. Júlíusson 
Klinikk/avdeling 
Barneklinikken, Haukeland 
Universitetssykehus 
All forskningsdeltakelse er frivillig. Dersom du på vegne av barnet sier ja til å delta, undertegner du 
denne samtykkeerklæringen. Om du nå sier ja til å delta, kan du senere når som helst og uten å oppgi 
noen grunn, trekke tilbake ditt samtykke uten at det påvirker barnets øvrige behandling. Dersom du 
eller barnet senere ønsker å trekke tilbake samtykket eller har spørsmål om forskningen, kan du 
kontakte prosjektleder. 
 
 
Jeg sier på vegne av barnet ja til at prøver og opplysninger om barnet brukes i forskning innen på 
barneovervekt 
 
Barnets navn med blokkbokstaver 
 
 
 
Barnets fødselsnummer (11 siffer) 
 
Dato 
 
 
 
Foresattes underskrift Rolle (mor/far/verge) 
 
Fylles ut av representant for forskningsområdet 
 
Jeg bekrefter å ha gitt informasjon om forskningsområdet: 
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Dato 
 
 
 
Underskrift Brukerkode (4-tegnskode) 
 
Eventuelle kommentarer: 
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6.3 Appendix III: Blood pressure tables 
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